LPEI-PEG Polyplex Targeted Cancer Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic agents like DNA or RNA face challenges in targeted delivery, particularly with non-viral vectors such as polyethylenimine-based polyplexes, due to toxicity and non-specific binding issues, leading to inefficient and heterogeneous product synthesis.
Innovation Solution
Development of a polyplex comprising linear polyethyleneimine (LPEI) covalently linked to polyethylene glycol (PEG) moieties, conjugated with a targeting moiety capable of binding to cancer antigens like EGFR or HER2, resulting in a reproducible and homogeneous pharmaceutical composition for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEI-based polyplexes are used for gene delivery, then transfection efficiency is improved, but toxicity increases due to high positive surface charge causing non-specific binding
Solution Approach 1:
The patent introduces PEG as an intermediary substance between the cationic PEI polymer and the cell surface. The PEG moiety acts as a mediator that reduces direct electrostatic interactions between the positively charged polyplex and negatively charged cell membranes, thereby decreasing non-specific binding and toxicity while maintaining targeted delivery capabilities through the attached targeting ligand.
Solution Approach 2:
The patent modifies the surface charge parameter of the polyplex by conjugating PEG to the PEI backbone. This chemical modification changes the electrostatic properties of the vector, reducing the net positive surface charge that causes toxicity, while preserving the cationic character necessary for nucleic acid condensation and cellular uptake.
2Reliability
If targeting ligands are conjugated to PEI-PEG to improve selectivity, then cancer cell targeting is enhanced, but product homogeneity decreases due to insufficiently homogeneous synthesis
Solution Approach 1:
The patent divides the conjugation process into distinct stages: first synthesizing PEI-PEG conjugates with controlled PEG incorporation, then separately preparing targeting ligands, and finally coupling them together. This segmented approach allows for better control of each reaction step, improving the homogeneity of the final product while maintaining the desired targeting selectivity.
Solution Approach 2:
The patent performs preliminary conjugation of PEG to PEI before attaching the targeting ligand. This preliminary action creates a standardized intermediate product (PEI-PEG) with controlled properties, which then serves as a uniform platform for subsequent ligand attachment, thereby improving overall product homogeneity while preserving targeting capabilities.
3Object-affected harmful factors
If PEG is conjugated to PEI to shield the particle and reduce toxicity, then biocompatibility is improved, but the complexity of synthesis increases
Solution Approach 1:
The patent creates a composite material structure by conjugating PEG to the PEI backbone, forming a PEI-PEG hybrid polymer. This composite approach combines the beneficial properties of both components: the cationic PEI core provides nucleic acid binding and cellular uptake capabilities, while the PEG shell provides steric stabilization and reduced toxicity, achieving improved biocompatibility through material composition rather than complex processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LPEI-PEG conjugates demonstrate enhanced selectivity and biocompatibility, achieving efficient gene delivery specifically to cancer cells overexpressing EGFR or HER2, with reduced toxicity and improved protection of nucleic acids from degradation, while maintaining transfection efficiency.
Implementation Method 1
PEIs are water-soluble, organic macromolecules that are available as both linear and branched structures. PEIs change their degree of ionization over a broad range of pH, since every third atom in their backbone chain is an amino nitrogen, that can be protonated. Approximately 55% of the nitrogens in PEIs are protonated at physiological pH. They possess high cationic charge density, and are therefore capable of forming non-covalent complexes with nucleic acids.
Implementation Method 2
PEI-based complexes (also known as polyplexes) can be endocytosed by many cell types. Following internalization of the polyplexes, endosome release and high efficiency gene transfer are driven by the 'proton sponge effect'.
Implementation Method 3
Following internalization of the polyplexes, endosome release and high efficiency gene transfer are driven by the 'proton sponge effect'.
Data Source
AI summary
A method of treating cancer may include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate may consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety may be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.